USPTO serial 75420278
Reviewed by CopyMark Law Group
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
151 85 SODERTALJE, SE
S-151 85 Sodertalje, SE
151 85 SODERTALJE, SE
S-151 85 Sodertalje, SE
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Wm. Charles Saunders
Wm. Charles Saunders AstraZeneca Pharmaceuticals LP1800 Concord PikeOW2Wilmington, DE 19850| Class | Description | Status | First use |
|---|---|---|---|
| 005 | PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM INCLUDING MULTIPLE SCLEROSIS | SECTION 8 - CANCELLED | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| May 16, 2009 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Feb 4, 2008 | CFIT | CASE FILE IN TICRS | — |
| Jul 24, 2007 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 24, 2007 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 24, 2002 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 2, 2002 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 12, 2002 | NPUB | NOTICE OF PUBLICATION | — |
| Mar 11, 2002 | PCGR | PETITION TO DIRECTOR GRANTED | — |
| Feb 9, 2002 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Feb 4, 2002 | PCRC | PETITION TO DIRECTOR RECEIVED | — |
| Aug 16, 2001 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 3, 2001 | EXT5 | SOU EXTENSION 5 FILED | — |
| Mar 9, 2001 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 7, 2001 | EXT4 | SOU EXTENSION 4 FILED | — |
| Aug 15, 2000 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jun 20, 2000 | EXT3 | SOU EXTENSION 3 FILED | — |
| Mar 30, 2000 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 18, 2000 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| Jan 25, 2000 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 26, 1999 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 28, 1999 | EXT1 | SOU EXTENSION 1 FILED | — |
| Feb 9, 1999 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 17, 1998 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 16, 1998 | NPUB | NOTICE OF PUBLICATION | — |
| Sep 8, 1998 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 7, 1998 | DOCK | ASSIGNED TO EXAMINER | — |